Biomarkers that indicate XBP1 activity could help identify patients who might benefit from therapies targeting the UPR. Levels of spliced XBP1 mRNA or protein can serve as potential biomarkers. Additionally, the expression of XBP1 target genes, such as those involved in protein folding and degradation, can provide insights into the activation status of XBP1 in tumors.